Clinical and Molecular Hepatology (Jan 2021)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis

  • Po-Yao Hsu,
  • Yu-Ju Wei,
  • Jia-Jung Lee,
  • Sheng-Wen Niu,
  • Jiun-Chi Huang,
  • Cheng-Ting Hsu,
  • Tyng-Yuan Jang,
  • Ming-Lun Yeh,
  • Ching-I Huang,
  • Po-Cheng Liang,
  • Yi-Hung Lin,
  • Ming-Yen Hsieh,
  • Meng-Hsuan Hsieh,
  • Szu-Chia Chen,
  • Chia-Yen Dai,
  • Zu-Yau Lin,
  • Shinn-Cherng Chen,
  • Jee-Fu Huang,
  • Jer-Ming Chang,
  • Shang-Jyh Hwang,
  • Wan-Long Chuang,
  • Chung-Feng Huang,
  • Yi-Wen Chiu,
  • Ming-Lung Yu

DOI
https://doi.org/10.3350/cmh.2020.0180
Journal volume & issue
Vol. 27, no. 1
pp. 186 – 196

Abstract

Read online

Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population. Methods The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan. Results Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean class number, 3.4). The most common comedication classes were ESRD-associated medications (94.1%), cardiovascular drugs (69.8%) and antidiabetic drugs (43.2%). ESRD-associated medications were excluded from DDI analysis. Sofosbuvir/velpatasvir/voxilaprevir had the highest frequency of potential contraindicated DDIs (red, 5.6%), followed by glecaprevir/pibrentasvir (4.0%), sofosbuvir/ledipasvir (1.3%), sofosbuvir/velpatasvir (1.3%), and elbasvir/grazoprevir (0.3%). For potentially significant DDIs (orange, requiring close monitoring or dose adjustments), sofosbuvir/velpatasvir/voxilaprevir had the highest frequency (19.9%), followed by sofosbuvir/ledipasvir (18.2%), glecaprevir/pibrentasvir (12.6%), sofosbuvir/velpatasvir (12.6%), and elbasvir/grazoprevir (7.3%). Overall, lipid-lowering agents were the most common comedication class with red-category DDIs to all DAA regimens (n=62), followed by cardiovascular agents (n=15), and central nervous system agents (n=10). Conclusions HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. Elbasvir/grazoprevir had the fewest potential DDIs, and sofosbuvir/velpatasvir/voxilaprevir had the most potential DDIs.

Keywords